Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN-CLL-321 pirtobrutinib versus investigator's choice in BTK inhibitor pretreated CLL/SLL
2023-507697-40-00Phase 3Authorised
- Sponsor
- Loxo Oncology
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by Loxo Oncology. Primary endpoint: Progression-free survival. Planned start Jul 2021; status: authorised.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-507697-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507697-40-00.